Recent News

• 10.21.2026 - Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
• 09.24.2026 - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
• 09.15.2026 - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
• 09.14.2026 - Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
• 09.02.2026 - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
• 08.31.2026 - Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
• 08.20.2026 - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
• 08.13.2026 - Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• 08.06.2026 - Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
• 07.14.2026 - Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

Recent Filings

• 10.16.2026 - 8-K/A Current report
• 09.29.2026 - 8-K Current report
• 08.25.2026 - 8-K Current report
• 08.24.2026 - 8-K Current report
• 08.20.2026 - D Notice of Exempt Offering of Securities
• 08.18.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2026 - 8-K Current report
• 08.13.2026 - EX-99.1 EX-99.1